{
  "ticker": "IIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969071",
  "id": "02969071",
  "pages": 33,
  "price_sensitive": true,
  "date": "20250714",
  "time": "1518",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06ls7w9g4674yq.pdf",
  "summary": "**INOVIQ Investor Briefing \u2013 Key Material Information**  \n\n- **EXO-OC Test Performance**:  \n  - 77% sensitivity (all-stage ovarian cancer), 100% sensitivity (Stage I/II), >99.6% specificity.  \n  - Retrospective study (n=497) validated AI algorithm; independent test set (n=125) confirmed accuracy (94.4% correct).  \n\n- **EXO-OC Commercialization**:  \n  - Targeting LDT pathway (CLIA lab partner) in H2 2025, followed by IVD regulatory pathway (US FDA PMA, CE-IVD).  \n  - Pivotal clinical study (10K\u201320K participants) planned for asymptomatic, post-menopausal women.  \n\n- **CAR-Exosome Therapeutics**:  \n  - Preclinical CAR-NK-EVs showed 88% TNBC and NSCLC cell kill in vitro.  \n  - Collaboration with Peter Mac for in vivo TNBC mouse model studies (H2 2025). Potential cost/logistical advantages vs. CAR-T.  \n\n- **Financials (31 March 2025)**:  \n  - Cash balance: **A$8.01m**.  \n  - Market cap: **A$41.9m** (share price: A$0.375).  \n\n- **Near-Term Catalysts**:  \n  - EXO-NET customer growth (>200%) and diagnostic partner signing.  \n  - IND-enabling studies for CAR-EVs (FY26).  \n\n**Omitted**: Operational details, leadership bios, forward-looking statements.  \n\n---  \n**Analysis**: Focuses on actionable data (clinical performance, funding runway, milestones) while excluding non-material updates. Format aligns with capital markets priorities.",
  "usage": {
    "prompt_tokens": 8877,
    "completion_tokens": 359,
    "total_tokens": 9236,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T06:19:05.109076"
}